Table 3.
Details of summary effects for various end points in patients with colorectal cancer according to intensive or control follow up. Figures are numbers (percentage) of patients and risk ratios (95% confidence interval)
| Intensive follow up | Control follow up | Fixed effects* | Random effects† | |
|---|---|---|---|---|
| All cause mortality | ||||
| Makela et al, 199517 | 23/52 (44) | 27/54 (50) | 0.88 (0.59 to 1.33) | |
| Ohlsson et al, 199518 | 15/53 (28) | 22/54 (41) | 0.69 (0.41 to 1.19) | |
| Schoemaker et al, 199819 | 43/167 (26) | 55/158 (35) | 0.74 (0.53 to 1.03) | |
| Pietra et al, 199820 | 28/104 (27) | 43/103 (42) | 0.64 (0.44 to 0.95) | |
| Subgroup‡ | 109/376 (29) | 148/369 (40) | 0.73 (0.60 to 0.89) | 0.74 (0.61 to 0.91) |
| Kjeldsen et al, 199721 | 88/290 (30) | 100/307 (33) | 0.93 (0.73 to 1.18) | |
| Pooled effect§ | 197/666 (30) | 247/676 (27) | 0.81 (0.70 to 0.94) | 0.81 (0.68 to 0.96) |
| All site recurrences | ||||
| Makela et al, 199517 | 22/52 (42) | 21/54 (39) | 1.09 (0.69 to 1.73) | |
| Ohlsson et al, 199518 | 17/53 (32) | 18/54 (33) | 0.96 (0.56 to 1.66) | |
| Schoemaker et al, 199819 | 56/167 (34) | 64/158 (41) | 0.83 (0.62 to 1.10) | |
| Pietra et al, 199820 | 41/104 (39) | 41/103 (40) | 0.99 (0.71 to 1.39) | |
| Subgroup‡ | 136/376 (36) | 144/367 (39) | 0.93 (0.77 to 1.12) | 0.93 (0.77 to 1.12) |
| Kjeldsen et al, 199721 | 76/290 (26) | 80/307 (26) | 1.01 (0.77 to 1.32) | |
| Pooled effect§ | 212/666 (32) | 224/676 (33) | 0.95 (0.82 to 1.11) | 0.95 (0.82 to 1.11) |
| All local recurrences | ||||
| Makela et al, 199517 | 10/52 (19) | 9/54 (17) | 1.15 (0.51 to 2.61) | |
| Ohlsson et al, 199518 | 11/53 (21) | 8/54 (15) | 1.40 (0.61 to 3.21) | |
| Schoemaker et al, 199819 | 7/167 (4) | 11/158 (7) | 0.60 (0.24 to 1.51) | |
| Pietra et al, 199820 | 26/104 (25) | 20/103 (19) | 1.29 (0.77 to 2.16) | |
| Subgroup‡ | 54/376 (14) | 48/367 (13) | 1.12 (0.79 to 1.52) | 1.14 (0.80 to 1.63) |
| Kjeldsen et al, 199721 | 49/290 (17) | 42/307 (14) | 1.24 (0.84 to 1.81) | |
| Pooled effect§ | 103/666 (15) | 90/676 (13) | 1.17 (0.91 to 1.52) | 1.19 (0.91 to 1.54) |
| Isolated local recurrences | ||||
| Makela et al, 199517 | 3/52 (6) | 2/54 (4) | 1.56 (0.27 to 8.95) | |
| Ohlsson et al, 199518 | Not stated | |||
| Schoemaker et al, 199819 | Not stated | |||
| Pietra et al, 199820 | 20/104 (19) | 8/103 (8) | 2.48 (1.14 to 5.37) | |
| Subgroup‡ | 23/156 (15) | 10/157 (6) | 2.30 (1.13 to 4.64) | 2.30 (1.13 to 4.66) |
| Kjeldsen et al, 199721 | 42/290 (14) | 32/307 (10) | 1.39 (0.90 to 2.14) | |
| Pooled effect§ | 65/446 (15) | 42/464 (9) | 1.61 (1.12 to 2.32) | 1.59 (1.10 to 2.30) |
| All hepatic metastases | ||||
| Makela et al, 199517 | 5/52 (10) | 2/54 (4) | 2.60 (0.53 to 12.8) | |
| Ohlsson et al, 199518 | 3/53 (6) | 7/54 (13) | 0.44 (0.12 to 1.60) | |
| Schoemaker et al, 199819 | 20/167 (12) | 23/158 (15) | 0.82 (0.47 to 1.44) | |
| Pietra et al, 199820 | 21/104 (20) | 32/103 (31) | 0.65 (0.40 to 1.05) | |
| Subgroup‡ | 49/376 (13) | 64/367 (17) | 0.75 (0.53 to 1.05) | 0.74 (0.50 to 1.10) |
| Kjeldsen et al, 199721 | 22/290 (8) | 27/307 (9) | 0.86 (0.50 to 1.48) | |
| Pooled effect§ | 71/666 (11) | 91/676 (13) | 0.78 (0.59 to 1.05) | 0.77 (0.58 to 1.03) |
| Isolated hepatic metastases | ||||
| Makela et al, 199517 | 2/52 (4) | 0/54 (0) | 5.19 (0.26 to 105) | |
| Ohlsson et al, 199518 | Not stated | |||
| Schoemaker et al, 199819 | 14/167 (8) | 12/158 (8) | 0.95 (0.47 to 1.92) | |
| Pietra et al, 199820 | 4/104 (4) | 3/103 (3) | 1.32 (0.30 to 5.75) | |
| Subgroup‡ | 20/323 (6) | 15/315 (5) | 1.13 (0.61 to 2.08) | 1.02 (0.51 to 2.02) |
| Kjeldsen et al, 199721 | Not stated | |||
| Pooled effect§ | 20/323 (6) | 15/315 (5) | 1.13 (0.61 to 2.08) | 1.02 (0.51 to 2.02) |
| All lung metastases | ||||
| Makela et al, 199517 | 1/52 (2) | 3/54 (6) | 0.35 (0.04 to 3.22) | |
| Ohlsson et al, 199518 | 3/53 (6) | 2/54 (4) | 1.53 (0.27 to 8.78) | |
| Schoemaker et al, 199819 | 8/167 (5) | 10/158 (6) | 0.76 (0.31 to 1.87) | |
| Pietra et al, 199820 | 0/104 (0) | 1/103 (1) | 0.33 (0.01 to 8.01) | |
| Subgroup‡ | 12/376 (3) | 16/367 (4) | 0.74 (0.36 to 1.51) | 0.75 (0.36 to 1.08) |
| Kjeldsen et al, 199721 | 7/290 (2) | 16/307 (5) | 0.46 (0.19 to 1.11) | |
| Pooled effect§ | 19/666 (3) | 32/676 (5) | 0.61 (0.35 to 1.05) | 0.62 (0.35 to 1.08) |
| Intraluminal recurrences | ||||
| Makela et al, 199517 | 2/52 (4) | 1/54 (2) | 2.08 (0.19 to 22.2) | |
| Ohlsson et al, 199518 | 2/53 (4) | 2/54 (4) | 1.02 (0.15 to 6.97) | |
| Schoemaker et al, 199819 | 3/167 (2) | 5/158 (3) | 0.57 (0.14 to 2.34) | |
| Pietra et al, 199820 | 1/104 (1) | 1/103 (1) | 0.99 (0.06 to 15.6) | |
| Subgroup‡ | 8/376 (2.1) | 9/367 (2.5) | 0.88 (0.34 to 2.23) | 0.87 (0.33 to 2.28) |
| Kjeldsen et al, 199721 | 10/134 (7) ¶ | 6/149 (4) ¶ | 1.85 (0.69 to 4.96) | |
| Pooled effect§ | 18/510 (3.5) | 15/518 (2.8) | 1.25 (0.64 to 2.44) | 1.26 (0.63 to 2.51) |
| Metachronous cancers | ||||
| Makela et al, 199517 | 1/52 (2) | 0/54 (0) | 3.11 (0.13 to 74.7) | |
| Ohlsson et al, 199518 | 0/53 (0) | 1/54 (2) | 0.34 (0.01 to 8.15) | |
| Schoemaker et al, 199819 | 3/167 (2) | 2/158 (1) | 1.42 (0.24.8.38) | |
| Pietra et al, 199820 | 0/104 (0) | 1/103 (1) | 0.33 (0.01 to 8.01) | |
| Subgroup‡ | 4/376 (1.1) | 4/367 (1.1) | 0.98 (0.30 to 3.19) | 1.01 (0.28 to 3.63) |
| Kjeldsen et al, 199721 | 7/290 (2) | 3/307 (1) | 2.47 (0.64 to 9.46) | |
| Pooled effect§ | 11/666 (1.7) | 7/676 (1.0) | 1.50 (0.63 to 3.54) | 1.55 (0.28 to 3.63) |
*
Mantel and Haenszel.
†
DerSimonian and Laird.
‡
Extramural detection trials.
§
Extramural and intramural detection trials.
¶
Data based on rectal cancers only.